MELVILLE, N.Y.--(BUSINESS WIRE)--Feb. 21, 2006--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that it has initiated a Phase IIa clinical trial for its glycogen phosphorylase inhibitor, PSN357, which the company is developing for type 2 diabetes. In the Phase IIa study, PSN357 will be administered to up to thirty type 2 diabetic patients as daily doses over an initial period of 14 days providing safety, pharmacokinetic and pharmacodynamic endpoints in a placebo controlled dose escalation design. The study is expected to last approximately six months.
